文献速递慢性静脉疾病

3%聚多卡醇泡沫盐水预冲与标准泡沫硬化疗法随机对照试验

A randomized controlled trial of 3% polidocanol foam with saline prewashing compared with standard foam sclerotherapy for the treatment of varicose veins.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-04-01

这项单中心前瞻性随机对照试验纳入35例(70条肢体)C2-C5级静脉曲张患者,比较3%聚多卡醇泡沫联合0.9%盐水预冲与1%聚多卡醇泡沫的疗效与安全性。

要点

  • 两组浅表血栓形成和色素沉着发生率低且无显著差异。

核心结论

  • 3% SALFOAM方法使用较低硬化剂体积即可达到与1%聚多卡醇泡沫相当的疗效和安全性。

研究设计与样本

  • 单中心前瞻性随机对照试验纳入35例(70条肢体)C2-C5级静脉曲张患者,1:1随机分组。

主要发现

  • 浅表血栓形成和色素沉着发生率低且无显著差异。
  • 修订版静脉临床评分两组无统计学显著差异,小样本量可能限制解读。

临床怎么用

  • 3%聚多卡醇泡沫联合盐水预冲可作为减少硬化剂用量的可选方法。
  • 需注意小样本量对临床评分等结果解读的限制。

局限性

  • 小样本量可能限制修订版静脉临床评分等结果的解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic venous disease is a highly prevalent global condition. Sclerotherapy with polidocanol foam is an established minimally invasive treatment. However, complications such as postprocedural hyperpigmentation remain common, and the maximum injectable volume per session may limit treatment efficacy. These factors highlight the need for optimized techniques to enhance vein occlusion and cosmetic outcomes. This study evaluated the efficacy and safety of 3% polidocanol foam with prewashing with saline compared with the conventional 1% polidocanol foam method. METHODS: This single-center, prospective, randomized controlled trial enrolled 35 patients (70 limbs) with Clinical Ethological Anatomical Pathophysiological class C2 to C5 varicose veins. Participants were randomized 1:1 to receive either 3% polidocanol foam with 0.9% saline prewashing and extrinsic compression using a low-density polyethylene cylinder at 20 to 30 mm Hg, or 1% polidocanol foam. Primary outcomes were venous occlusion at day 90 on Doppler ultrasound examination and foam volume. Secondary outcomes were superficial venous thrombosis, hyperpigmentation, and quality of life, assessed using the revised Venous Clinical Score at baseline and day 90. RESULTS: Thirty-one patients (62 limbs) completed the study (16 in the 3% polidocanol plus saline prewashing group; 15 in the 1% polidocanol group). Baseline characteristics were comparable across treatment arms. No major adverse events occurred. Occlusion rates were similar between the groups (P = .80). The 3% polidocanol foam technique achieved comparable occlusion using significantly less foam volume (0.27 ± 0.21 mL vs 0.54 ± 0.28 mL; P < .001). Rates of superficial thrombosis and hyperpigmentation were low and did not differ significantly. No statistically significant difference in the revised Venous Clinical Score was observed between groups; the small sample size may limit interpretation of these findings. CONCLUSIONS: The 3% SALFOAM method can be used with comparable efficacy and safety while using a lower sclerosant volume.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Rocha LAF, Parente JBF, da Silva VS, et al. A randomized controlled trial of 3% polidocanol foam with saline prewashing compared with standard foam sclerotherapy for the treatment of varicose veins. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 41933831. doi:10.1016/j.jvsv.2026.102495

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。